These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37951315)

  • 21. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation.
    Nguyen TH; Hanley T; Porter CJ; Larson I; Boyd BJ
    J Pharm Pharmacol; 2010 Jul; 62(7):856-65. PubMed ID: 20636873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
    Mohsin K
    AAPS PharmSciTech; 2012 Jun; 13(2):637-46. PubMed ID: 22547370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of lipid-based SEDDS using digestion products of long-chain triglyceride for high drug solubility: Formulation and dispersion testing.
    Desai HH; T M Serajuddin A
    Int J Pharm; 2024 Apr; 654():123953. PubMed ID: 38417725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caco-2 Cell Conditions Enabling Studies of Drug Absorption from Digestible Lipid-Based Formulations.
    Keemink J; Bergström CAS
    Pharm Res; 2018 Feb; 35(4):74. PubMed ID: 29484506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations.
    Kaukonen AM; Boyd BJ; Porter CJ; Charman WN
    Pharm Res; 2004 Feb; 21(2):245-53. PubMed ID: 15032305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs.
    Holm R; Jørgensen EB; Harborg M; Larsen R; Holm P; Müllertz A; Jacobsen J
    Eur J Pharm Sci; 2011 Mar; 42(4):416-22. PubMed ID: 21256961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapad
    Ilie AR; Griffin BT; Brandl M; Bauer-Brandl A; Jacobsen AC; Vertzoni M; Kuentz M; Kolakovic R; Holm R
    Eur J Pharm Sci; 2020 Sep; 152():105452. PubMed ID: 32622980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrinsic lipolysis rate for systematic design of lipid-based formulations.
    Jacobsen AC; Kabedev A; Sinko PD; Palm JE; Bergström CAS; Teleki A
    Drug Deliv Transl Res; 2023 May; 13(5):1288-1304. PubMed ID: 36209313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
    Williams HD; Sassene P; Kleberg K; Calderone M; Igonin A; Jule E; Vertommen J; Blundell R; Benameur H; Müllertz A; Porter CJ; Pouton CW;
    J Pharm Sci; 2014 Aug; 103(8):2441-55. PubMed ID: 24985238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparisons of in vitro Fick's first law, lipolysis, and in vivo rat models for oral absorption on BCS II drugs in SNEDDS.
    Ye J; Wu H; Huang C; Lin W; Zhang C; Huang B; Lu B; Xu H; Li X; Long X
    Int J Nanomedicine; 2019; 14():5623-5636. PubMed ID: 31440045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
    Porter CJ; Kaukonen AM; Taillardat-Bertschinger A; Boyd BJ; O'Connor JM; Edwards GA; Charman WN
    J Pharm Sci; 2004 May; 93(5):1110-21. PubMed ID: 15067688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.
    Boyd BJ; Khoo SM; Whittaker DV; Davey G; Porter CJ
    Int J Pharm; 2007 Aug; 340(1-2):52-60. PubMed ID: 17467935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids.
    Kaukonen AM; Boyd BJ; Charman WN; Porter CJ
    Pharm Res; 2004 Feb; 21(2):254-60. PubMed ID: 15032306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs.
    Suys EJA; Brundel DHS; Chalmers DK; Pouton CW; Porter CJH
    J Control Release; 2021 Mar; 331():45-61. PubMed ID: 33450318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.
    Porter CJ; Kaukonen AM; Boyd BJ; Edwards GA; Charman WN
    Pharm Res; 2004 Aug; 21(8):1405-12. PubMed ID: 15359575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations.
    Siqueira SD; Müllertz A; Gräeser K; Kasten G; Mu H; Rades T
    AAPS J; 2017 Mar; 19(2):587-594. PubMed ID: 28070714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA; Chalmers DK; Pouton CW; Porter CJH
    Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS).
    Thomas N; Holm R; Müllertz A; Rades T
    J Control Release; 2012 May; 160(1):25-32. PubMed ID: 22405903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlling drug release by introducing lipase inhibitor within a lipid formulation.
    Murshed M; Pham A; Vithani K; Salim M; Boyd BJ
    Int J Pharm; 2022 Jul; 623():121958. PubMed ID: 35760262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation.
    Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y
    Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.